US Patent

US9737488 — Pharmaceutical composition for the treatment of cancer

Method of Use · Assigned to Bayer Healthcare LLC · Expires 2028-09-10 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition for treating cancer, either alone or in combination with other cancer therapies.

USPTO Abstract

The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.

Drugs covered by this patent

sorafenib-tosylate (SORAFENIB TOSYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2107`	—	sorafenib-tosylate

Patent Metadata

Patent number: US9737488
Jurisdiction: US
Classification: Method of Use
Expires: 2028-09-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Bayer Healthcare LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.